Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4852422 | 0.87 | TRPV1 (0.58) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL30765433 | 0.87 | TRPV1 (0.52) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL11314328 | 0.87 | TRPV1 (0.52) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL17459887 | 0.87 | TRPV1 (0.52) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL1269411 | 0.85 | KDM4E (0.69) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL8742702 | 0.81 | KDM4E (0.70) | TRPV1KDM4EMEN1MAPTRAB9A | |
| SCHEMBL1741823 | 0.80 | KDM4E (0.71) | KDM4EMEN1MAPTRAB9AKMT2A | |
| SCHEMBL30227787 | 0.80 | KDM4E (0.71) | KDM4EMEN1MAPTRAB9AKMT2A | |
| SCHEMBL2676769 | 0.79 | TRPV1 (0.70) | TRPV1KDM4EMEN1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL9438453 | 0.78 | KDM4E (0.69) | KDM4EMEN1MAPTRAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084640-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885KDM4E 3248/4885MEN1 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.